Results from four studies within a major Roche-run clinical trials program of an investigational gut disease drug have muddled the antibody’s path forward after its performance proved mixed.
The company has been studying etrolizumab, an antibody designed to block two members... Read more »
[Updated 12:37 p.m.] An experimental Seres Therapeutics capsule of live bacteria has met the goals of a pivotal study evaluating it as a treatment for a type of recurrent gut infection, preliminary results the company says put it on... Read more »
The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home.
Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and... Read more »
AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic medicines alliance the pharmaceutical company exited this week.
The Editas therapy, EDIT-101, is in Phase 1 testing as... Read more »
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments.... Read more »
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said.
“Both trials appeared to be well designed,” based on publicly available information, said Ira Longini, co-director of... Read more »
Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells.
The agency OK’d the London-based pharma giant’s cancer... Read more »
Three early employees of G1 Therapeutics have launched a new oncology-focused company and raised $6 million to move a preclinical program licensed from their former employer into the clinic.
The startup, Research Triangle Park, NC-based Arc Therapeutics, is headed by Patrick... Read more »
Denali Therapeutics has selected a brain-penetrating Parkinson’s disease drug candidate to advance to late-stage testing, and Biogen is paying $1 billion to kick off a partnership on that compound and potentially others.
According to terms of the deal announced Thursday, the... Read more »
About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that and other common allergies.
The six-person startup, which is based out of the... Read more »
Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients to seek ways to manage their health from home.
Teladoc (NYSE: TDOC) provides... Read more »
One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It’s a particularly pronounced problem for therapies employing regulatory T cells (Tregs), a type of immune cell that’s relatively scarce in the blood, says... Read more »
A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs to change its design and run another clinical trial testing the modified... Read more »